Randomized trial: Plasma therapy administered early is beneficial in high-risk elderly patients

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults – New England Journal of Medicine

Commentaries: Early convalescent plasma may lower risk of severe COVID in seniors – CIDRAP AND Covid-19: Early Plasma Treatment Improved Outcomes in Older Patients – Physician’s Weekly

Commentaries on Twitter

Just published @NEJM: A small, placebo-controlled randomized trial (N=160) of high IgG titer convalescent plasma administered early (within 72 hrs) for mild covid-19 to older adults (median age >70) shows benefit https://t.co/dhyFH4OwpH pic.twitter.com/14lMBBofUh

— Eric Topol (@EricTopol) January 6, 2021

Early convalescent plasma may lower risk of severe COVID in seniors@NEJM study finds that 16% of those treated with high-titer convalescent therapy developed severe #COVID19, compared with 31% in the placebo grouphttps://t.co/7hqCXsNHDM pic.twitter.com/dZDUwcjxUh

— CIDRAP (@CIDRAP) January 6, 2021